Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to discovering, developing, and commercializing oral antiviral therapies aimed at treating severe viral diseases. Founded in 2012, Atea focuses on addressing unmet medical needs, particularly in serious viral infections caused by single-stranded RNA viruses.
The company's leading product candidate is AT-527 (bemnifosbuvir), an antiviral agent developed for treating COVID-19, caused by the SARS-CoV-2 virus. Currently, AT-527 is undergoing Phase 3 clinical trials. Additionally, the combination of bemnifosbuvir and ruzasvir, an oral NS5A inhibitor, is being developed for treating Hepatitis C Virus (HCV) and has shown promising results in Phase 2 trials. This combination therapy aims to provide a highly potent pan-genotypic antiviral treatment with a short treatment duration and fewer contraindications, particularly beneficial for HCV patients.
Beyond COVID-19 and HCV, Atea is also advancing other antiviral therapies in its pipeline, including AT-787 for Hepatitis C (under Phase 2 clinical trial), AT-752 for Dengue (under Phase 2 trial), and other candidates like AT-889 and AT-934 for Respiratory Syncytial Virus (currently under clinical trials).
Recent achievements include positive initial data from a Phase 2 study of bemnifosbuvir and ruzasvir for HCV, showing a 97% sustained virologic response rate at 12 weeks post-treatment. Furthermore, Atea has completed enrollment for the Phase 3 SUNRISE-3 trial for treating high-risk COVID-19 patients, with results expected in the second half of 2024.
Financially, Atea reported a solid cash position of $578.1 million as of December 31, 2023, enabling them to continue advancing their clinical programs. Collaborations and strategic partnerships play a crucial role in Atea’s progress, helping to broaden its scope and enhance its therapeutic offerings.
Investors and stakeholders can stay informed about Atea’s developments through their regular updates, financial reports, and participation in industry conferences. For more information, visit their official website at www.ateapharma.com.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi will present a business update at the Jefferies London Healthcare Conference on November 15, 2022, at 5:00 p.m. GMT / 12:00 p.m. ET. The event will be accessible via a live webcast and archived for 90 days post-event. Atea focuses on developing oral therapies for severe viral infections, leveraging its nucleos(t)ide prodrug platform. Current efforts include targeting COVID-19, hepatitis C, and other severe viral diseases.
Atea Pharmaceuticals (Nasdaq: AVIR) announced key updates and financial results for Q3 2022, reporting a net loss of $8.1 million, down from a loss of $28.2 million in 2021. The company holds $665 million in cash and marketable securities. Notably, the SUNRISE-3 trial for bemnifosbuvir in high-risk COVID-19 patients is set to enroll before year-end 2022. Additionally, Atea plans to submit trial applications for a hepatitis C combination study. Research and development expenses decreased significantly, attributed to the termination of a cost-sharing agreement with Roche.
Atea Pharmaceuticals (AVIR) provided updates on AT-752, an oral antiviral for dengue fever, during the ASTMH 2022 Annual Meeting. The Phase 1 trial showed that AT-752 was well tolerated at doses up to 1500 mg, achieving plasma levels above the in vitro EC90. The FDA has given Fast Track designation for AT-752, making it a promising option for treating dengue, which affects 400 million annually. Atea is advancing two proof-of-concept studies to evaluate AT-752's safety and efficacy against dengue, aiming to fill the existing treatment gap.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) will host a live conference call on November 7, 2022, at 4:30 p.m. ET, to report financial results for Q3 2022 and provide a business update. The call can be accessed via registration, with a webcast available in the Investor Relations section of the company's website. Atea focuses on developing oral therapies for severe diseases, particularly targeting ssRNA viruses, including SARS-CoV-2, HCV, dengue, and RSV. The company aims to expand its antiviral pipeline through its proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that the FDA granted Fast Track Designation to AT-752, an oral antiviral for dengue treatment. This designation aims to expedite development, acknowledging the urgent need for effective treatments as there are currently no approved options. AT-752 has shown promising preclinical activity against dengue and safety in Phase 1 trials. The company is advancing two Phase 2 studies to assess AT-752’s efficacy and safety in adults with dengue virus infections, with initial data expected soon.
Atea Pharmaceuticals (Nasdaq: AVIR) announced a global Phase 3 trial to assess bemnifosbuvir for COVID-19, beginning in Q4 2022. The trial targets high-risk non-hospitalized patients, evaluating bemnifosbuvir as both monotherapy and in combination with other treatments. Previous trials indicated a 71% reduction in hospitalization rates. The randomized, double-blind study aims to enroll 1,500 patients across 300 sites worldwide, focusing on safety and efficacy against various COVID-19 variants. Positive early results emphasize bemnifosbuvir's potential as a cornerstone therapy for COVID-19 treatment.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in key investor events on September 13, 2022. The management will host a conference call at 8:30 a.m. ET to detail the global Phase 3 trial of bemnifosbuvir for COVID-19 treatment. Additionally, CEO Jean-Pierre Sommadossi will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 12:55 p.m. ET. Live webcasts of these events will be available on Atea's website.
Atea Pharmaceuticals (AVIR) is advancing bemnifosbuvir into late-stage clinical trials for COVID-19 after discussions with the FDA and EMA. New data show bemnifosbuvir retains antiviral activity against the Omicron variant. The company is also enrolling in Phase 2 trials for dengue and preparing for a Phase 2 trial for HCV. Financially, Atea reported a net loss of $31.3 million for Q2 2022, a significant drop from a net income of $1.5 million in Q2 2021, driven by the loss of collaboration revenue from Roche.
Atea Pharmaceuticals (AVIR) announced a live conference call for August 8, 2022, at 4:30 p.m. ET to discuss its Q2 financial results and provide a business update. The company focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C. This event will be accessible via registration and a live webcast on their investor relations website. Atea emphasizes its commitment to advancing its nucleos(t)ide prodrug platform for treating RNA viruses. They also caution about risks associated with forward-looking statements.
Atea Pharmaceuticals (Nasdaq: AVIR) announced participation in the William Blair Biotech Focus Conference, with a pre-recorded fireside chat available from July 11, 2022, at 9:00 a.m. ET. The company focuses on developing oral antiviral therapies for severe diseases, utilizing its proprietary nucleos(t)ide prodrug platform. Current efforts include treatments for COVID-19, hepatitis C, dengue, and RSV. Atea emphasizes its commitment to advancing antiviral candidates through ongoing research and development.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
What is Atea Pharmaceuticals, Inc.?
What are the main products developed by Atea Pharmaceuticals?
What is the status of the AT-527 (bemnifosbuvir) clinical trials?
What recent achievements has Atea Pharmaceuticals made?
Where is Atea Pharmaceuticals headquartered?
How does Atea Pharmaceuticals plan to address unmet medical needs?
What is the financial condition of Atea Pharmaceuticals?
How can I get more information about Atea Pharmaceuticals?
What are the expected upcoming events for Atea Pharmaceuticals?
Who should be interested in Atea Pharmaceuticals’ updates?
